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A B S T R A C T
Osteoporosis is a complication of permanent androgen deprivation in men with prostate carcinoma, following ei-
ther bilateral orchiectomy or treatment with GnRH agonists. The present approach to the problem of osteoporosis in-
cludes prevention, adequate follow-up and appropriate treatment as an imperative of contemporary urological and
endocrinological management of these patients. Bone densitometry was performed in 18 patients who were on GnRH
agonists treatment during 1–3 years. The patients under therapy were followed clinically, PSA (prostate-specific anti-
gen) values were determined and bone scintigraphy was performed. The bone mineral density values in 13 patients in-
dicated osteopenia, whereas in one patient the finding was compatible with osteoporosis. Four patients had normal
bone mineral density findings. Bone densitometry should be performed before initiation of treatment with GnRH ago-
nists in order to quantify the therapy-related bone loss. Prevention of development of osteoporosis and its complications
depends on the assessment of pharmacological treatment in this group of patients, including e.g. bisphosphonates and
possible intermittent androgen deprivation.
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Introduction
Osteoporosis represents a special concern for men
with prostate carcinoma1. It is well known that osteopo-
rosis is not a disease that affects only women.
Androgen deprivation therapy by either bilateral
orchiectomy, gonadotropin-releasing hormone (Gn-RH)
agonist treatment or combined androgen blockade de-
creases bone mineral density and increases fracture
risk in men with prostate cancer2–4.
Bone mineral density is inversely correlated with
fracture risk in men and women5–7.
Men experience approximately 33% of all hip frac-
tures and mortality after hip fractures is even higher in
men than in women8.
Early primary androgen-deprivation therapy improves
survival for men with locally advanced, nonmetastatic
prostate cancer9. Adjuvant androgen-deprivation therapy
improves survival for men with lymph-node positive pros-
tate cancer treated with radical prostatectomy and pelvic
lymphadenectomy10 as well as in men with locally ad-
vanced prostate cancer treated with radiation therapy11.
A Working Group of the World Health Organization
(WHO) has defined normal finding, osteopenia, and os-
teoporosis in women based on bone mineral density
(BMD) compared with the value in young adults.
The long-term side effects of androgen deprivation
therapy have become increasingly important, however,
they are seldom considered by either patients or physi-
cians, since the male population receiving endocrine
therapy for prostate cancer has recently grown to in-
clude apparently healthy subjects with a rather low risk
of disease progression and relatively long life expect-
ancies12,13.
Patients and Methods
Between 1999 and 2002 bone densitometry was per-
formed in 18 patients with prostate carcinoma who were
on permanent androgen deprivation with GnRH-ago-
nists (duration of therapy range from at least 12 up to
36 months).
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Treatment modalities included LH-RH hormone an-
alogues (buserelin acetate, goserelin), and total andro-
gen blockade with an LH-RH analogue and nonsteroidal
anti-androgen.
The patients were followed clinically, including de-
termination of PSA (prostate-specific antigen) values
and bone scintigraphy. Patients had locally advanced,
lymph node positive, or recurrent prostate carcinoma,
with no radiographic evidence of bone metastases.
Since the understanding of the issue of osteoporosis
and its complications is a relatively new aspect of fol-
low-up, especially in this group of patients, densito-
metry was not performed before treatment initiation,
but after therapy duration of 1–3 years.
The patients did not have concomitant bone meta-
bolic disease, primary hyperparathyroidism or chronic
hypercortisolism, as recorded by medical history. They
had no prior hormonal treatment, and no prior or con-
comitant treatment with bisphosphonates or other drugs
known to affect bone metabolism.
World Health Organization classification of osteopo-
rosis was applied: (T-scores –1 were considered nor-
mal, scores of <–1 and up to –2.5 were considered
osteopenic, and scores –2.5 were considered osteopo-
rotic).
However, whether the same limits should be used in
men is still controversial, because men have larger
bones and a higher peak bone mass. Bone mineral den-
sity was determined by dual-energy X-ray absorption
(DEXA) in three centers. DEXA measurements of lum-
bar vertebrae L2-L4, total hip, femoral neck and tro-
chanteric region were evaluable for all patients.
BMD was expressed in standard deviation units rel-
ative to young adults (T score).
Subsequently, 99m-Technetium methylene diphos-
phate whole body bone scanning was performed.
Results
The values of bone mineral density ranged within
limits that define osteopenia in 13 patients. The treat-
ment duration in this group of patients was 24–36
months. The patient age was 53–78 years.
Osteoporosis was diagnosed by measurement of bone
mineral density in one patient. The patient had been on
permanent androgen deprivation for 18 months and
aged 74.
The bone mineral density values were normal in 4
patients, with therapy duration between 12 and 36
months. The patients’ age was 57–74 years.
One patient, aged 74, who was diagnosed with osteo-
porosis based on measurement of bone mineral density
had been on treatment for 18 months. Another patient,
also aged 74, had been on therapy for 3 years, yet had a
normal BMD finding (Table 1).
All men had stable and normal PSA levels (<4.0
ng/mL).
Discussion
Androgen-deprivation therapy is prescribed with in-
creasing frequency for men with prostate carcinoma.
There is growing concern about the effects of such ther-
apy on the skeleton14. There are also some other factors
that can contribute to fracture risk as diet, smoking,
lifestyle, and treatment-related loss of lean body mass15.
The specific subgroup of male patients featuring possi-
ble osteoporosis represents another example of bone loss
related to sex differences16.
The results of BMD measurement in a small group of
patients suggest that there is loss of bone mass in most
of patients and that measurement of bone mineral den-
sity should be performed before initiation of GnRH-
-agonists treatment, since this therapy accelerates bone
loss and increases fracture risk. Androgen deprivation
therapy may increase fracture risk by decreasing both
BMD and lean body mass15,17. There is no recommended
time limit for LH-RH hormone analogue therapy, and so
it is expected that many patients will ultimately be
treated for a long time18.
Results of a study by Smith et al. suggested that rou-
tine BMD screening is warranted in hormone-naive
men and the additional risks of treatment related bone
loss may influence individual decisions about the timing
and duration of androgen-deprivation therapy1.
The effect of intermittent androgen deprivation on
bone mineral density was reported by Higano et al. In
this series 9 months of combined androgen deprivation
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1. 12 57 –0.44 –0.4 normal
2. 18 61 0.4 –0.3 normal
3. 36 74 1.0 0.0 normal
4. 12 72 0.28 0.49 normal
5. 24 56 –1.1 –1.7 osteopenia
6. 12 69 –1.1 0.51 osteopenia
7. 36 53 –1.77 –2.01 osteopenia
8. 16 60 –1.4 –1.7 osteopenia
9. 14 69 –1.1 0.1 osteopenia
10. 24 78 –1.1 –1.7 osteopenia
11. 24 70 –1.39 –1.76 osteopenia
12. 12 65 –1.2 –1.5 osteopenia
13. 15 67 –1.1 –1.6 osteopenia
14 20 71 –1.4 –2.0 osteopenia
15. 18 68 –1.0 –1.7 osteopenia
16. 14 64 –1.1 –2.0 osteopenia
17. 18 69 –1.1 –1.3 osteopenia
18. 18 74 –2.33 –3.7 osteoporosis
therapy was followed by an off period, in which andro-
gen deprivation therapy was withheld until PSA in-
creased to a predetermined threshold. An increased
BMD in the period of rest suggests that this treatment
modality may be advantageous over continuous admin-
istration for limiting bone loss19.
Several studies published up to date have suggested
that treatment with bisphosphonates may prevent bone
loss in the hip and lumbar spine during androgen depri-
vation therapy20,21. Additional studies are necessary to
evaluate the effects of oral bisphosponates on BMD and
fracture risk in men receiving androgen deprivation
therapy for prostate carcinoma15.
Recent studies indicate that for men with prostate
carcinoma who are at high risk for osteoporosis and
fractures, clinical management should be dictated by
the results of radiographic and DXA skeletal asses-
sment14.
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PROMJENE MINERALNE GUSTO]E KOSTIJU U BOLESNIKA S KARCINOMOM PROSTATE
NAKON ANDROGENE DEPRIVACIJE
S A @ E T A K
Osteoporoza je komplikacija trajne androgene deprivacije u mu{karaca s karcinomom prostate. Ona nastaje kao
posljedica bilo bilateralne orhidektomije ili primjenom agonista GnRH. U dana{njem pristupu problemu osteoporoze,
prevencija i odgovaraju}e pra}enje bolesnika, te terapija, name}u se kao imperativ suvremenog urolo{kog i endo-
krinolo{kog lije~enja. U 18 bolesnika koji su bili na terapiji GnRH agonistima u trajanju od 1–3 godine, u~injena je
denzitometrija kostiju. Bolesnici su za vrijeme trajanja terapije pra}eni klini~ki, odre|ivane su vrijednosti PSA, te je
u~injena scintigrafija skeleta. U 13 bolesnika vrijednosti mineralne gusto}e kostiju upu}ivale su na osteopeniju, a
kod jednog bolesnika nalaz je govorio u prilog osteoporozi. U ~etiri bolesnika nalaz mineralne gusto}e kostiju bio je
potpuno uredan. Prije uklju~ivanja pacijenata u terapiju GnRH agonistima nu`no je u~initi denzitometriju kostiju da
bi se mogao kvantificirati gubitak induciran terapijom. U cilju prevencije razvoja ostoporoze kao i njenih kompli-
kacija, u ovoj grupi bolesnika nu`no je stoga procijeniti i potrebu za medikamentoznim pristupom bolesti npr. bis-
fosfonatima, uz eventualnu intermitentnu androgenu deprivaciju.
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